Article
Conceptual Framework for Cutting the Pancreatic Cancer Fuel Supply
14 Aug 2012
Abstract excerpt
Pancreatic ductal adenocarcinoma (a.k.a. pancreatic cancer) remains one of the most feared and clinically challenging diseases to treat despite continual improvements in therapies. The genetic landscape of pancreatic cancer shows near ubiquitous activating mutations of KRAS, and recurrent inactivating mutations of CDKN2A, SMAD4, and TP53. To date, attempts to develop agents to target KRAS to specifically kill...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.
